

Gregory J Riely

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/170908/publications.pdf>

Version: 2024-02-01

178
papers

53,160
citations

5126

86
h-index

5481

169
g-index

181
all docs

181
docs citations

181
times ranked

40344
citing authors

#	ARTICLE	IF	CITATIONS
1	CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors. <i>Annals of Thoracic Surgery</i> , 2022, 113, 957-965.	0.7	12
2	<i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. <i>Cancer Discovery</i> , 2022, 12, 562-585.	7.7	48
3	Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100256.	0.6	4
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
5	A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100105.	1.0	5
6	Encorafenib plus binimetinib in patients with <i>BRAF</i> ^{V600} -mutant non-small cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	1.1	9
7	Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation. <i>JAMA Network Open</i> , 2022, 5, e223687.	2.8	4
8	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	2.9	8
9	Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 497-530.	2.3	530
10	Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> ^{G12C} Mutation. <i>New England Journal of Medicine</i> , 2022, 387, 120-131.	13.9	269
11	Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100367.	0.6	13
12	Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced <i>EGFR</i> mutant lung cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, 9100-9100.	0.8	0
13	Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥5%) T1-2 N0-1 NSCLC. <i>Journal of Clinical Oncology</i> , 2022, 40, 9084-9084.	0.8	0
14	KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a <i>KRAS</i> ^{G12C} mutation. <i>Journal of Clinical Oncology</i> , 2022, 40, 9002-9002.	0.8	22
15	Clinicopathologic and mutational landscape of <i>BRAF</i> ^{V600E} -mutant non-small cell lung carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9084-9084.	0.8	0
16	Mobocertinib (TAK-788) in <i>EGFR</i> exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD. <i>Journal of Clinical Oncology</i> , 2022, 40, 9099-9099.	0.8	5
17	Assessing effectiveness of first-line carboplatin, pemetrexed, and pembrolizumab in patients with recurrent/metastatic lung adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, e21045-e21045.	0.8	0
18	Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 3323-3343.	0.8	63

#	ARTICLE	IF	CITATIONS
19	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 3310-3322.	0.8	60
20	Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. <i>Cancer Discovery</i> , 2021, 11, 59-67.	7.7	38
21	Erlotinib and Trametinib in Patients With <i>EGFR</i>-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2021, 5, 55-64.	1.5	10
22	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12Câ€“Mutant Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2209-2215.	3.2	65
23	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2604-2612.	3.2	20
24	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Nonâ€“Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	7.7	154
25	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. <i>JAMA Surgery</i> , 2021, 156, e205601.	2.2	52
26	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 1040-1091.	0.8	192
27	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <i>EGFR</i> Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021, 27, 2920-2927.	3.2	42
28	Pilot Study of Dacomitinib for Patients With Metastatic <i>EGFR</i>-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. <i>JCO Precision Oncology</i> , 2021, 5, 695-700.	1.5	9
29	Pan-cancer evaluation of homologous repair deficiency somatic mutations and response to first-line anti-neoplastic therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10535-10535.	0.8	1
30	Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9088-9088.	0.8	4
31	Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2032-2032.	0.8	2
32	Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 550-560.	1.0	4
33	Acquired Resistance to KRAS^{G12C} Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2382-2393.	13.9	482
34	Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research. <i>Cancer Cell</i> , 2021, 39, 897-899.	7.7	1
35	The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.3	0
36	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	0.9	17

#	ARTICLE	IF	CITATIONS
37	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, e214761.	3.4	160
38	Diverse alterations associated with resistance to KRAS(G12C) inhibition. <i>Nature</i> , 2021, 599, 679-683.	13.7	183
39	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265.	0.5	53
40	Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 705-714.e1.	0.4	18
41	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 231-247.	0.5	172
42	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5701-5708.	3.2	133
43	CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. <i>JCO Precision Oncology</i> , 2020, 4, 871-876.	1.5	14
44	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers. <i>JAMA Oncology</i> , 2020, 6, 1048.	3.4	96
45	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. <i>Clinical Cancer Research</i> , 2020, 26, 2932-2945.	3.2	35
46	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 561-572.	5.2	47
47	Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1608-1632.	0.8	301
48	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2654-2663.	3.2	230
49	Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9574-9574.	0.8	4
50	Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9596-9596.	0.8	2
51	Progression-free survival estimates in non-small cell lung cancer when RECIST is unavailable: Project GENIE's integration of genomic, therapeutic and phenomic data.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9622-9622.	0.8	0
52	YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21591-e21591.	0.8	0
53	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1063-1069.	3.2	257
54	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	31

#	ARTICLE	IF	CITATIONS
55	Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1784-1793.	0.5	232
56	Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. <i>Acta Oncologica</i> , 2019, 58, 1634-1639.	0.8	10
57	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1691-1701.	5.1	233
58	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. <i>Clinical Cancer Research</i> , 2019, 25, 7113-7125.	3.2	69
59	Frequency and outcomes of brain metastases in patients with HER2 mutant lung cancers. <i>Cancer</i> , 2019, 125, 4380-4387.	2.0	51
60	Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 764.	3.8	720
61	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2019, 14, 802-815.	0.5	71
62	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003665.	0.5	23
63	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	26
64	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
65	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 575-583.	3.0	96
66	Improving therapy for patients with epidermal growth factor receptor mutant lung cancer. <i>Cancer</i> , 2018, 124, 2272-2275.	2.0	1
67	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3108-3118.	3.2	200
68	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340.	3.2	323
69	Twice weekly pulse and daily continuous dose erlotinib as initial treatment for patients with epidermal growth factor receptor mutant lung cancers and brain metastases. <i>Cancer</i> , 2018, 124, 105-109.	2.0	25
70	Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	60
71	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537.	0.8	381
72	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	0.8	747

#	ARTICLE	IF	CITATIONS
73	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
74	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology</i> , 2018, 19, 1654-1667.	5.1	587
75	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1595-1601.	0.5	137
76	Type A thymoma presenting with bone metastasis. <i>Histopathology</i> , 2018, 73, 701-703.	1.6	1
77	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	0.5	62
78	<i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6030-E6038.	3.3	44
79	The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis. <i>Clinical Lung Cancer</i> , 2017, 18, 255-258.	1.1	2
80	Targeting ALK: Precision Medicine Takes on Drug Resistance. <i>Cancer Discovery</i> , 2017, 7, 137-155.	7.7	405
81	Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer—Incidence, radiological features and clinical characteristics. <i>Lung Cancer</i> , 2017, 106, 33-36.	0.9	20
82	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
83	Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 101-111.	0.9	32
84	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	7.7	490
85	Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. <i>Lung Cancer</i> , 2017, 108, 109-114.	0.9	36
86	Radiogenomic evaluation of lung cancer—Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?. <i>Clinical Imaging</i> , 2017, 42, 147-151.	0.8	14
87	Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. <i>Journal of Thoracic Oncology</i> , 2017, 12, 745-751.	0.5	23
88	A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 102-109.	0.5	40
89	Identification and Functional Characterization of <i>EGFR</i> V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	9
90	Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. <i>Journal of Oncology Practice</i> , 2017, 13, 780-783.	2.5	3

#	ARTICLE	IF	CITATIONS
91	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3484-3515.	0.8	492
92	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266
93	A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers. <i>Journal of Clinical Oncology</i> , 2017, 35, 9033-9033.	0.8	6
94	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. <i>PLoS ONE</i> , 2017, 12, e0182665.	1.1	54
95	Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 642-650.	5.1	352
96	Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 903-911.	1.2	20
97	Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , 2016, 17, 1653-1660.	5.1	365
98	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 234-242.	5.1	574
99	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, e121-e129.	1.1	116
100	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2351-2358.	3.2	141
101	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. <i>Clinical Cancer Research</i> , 2016, 22, 1103-1110.	3.2	326
102	Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis. <i>Journal of Thoracic Oncology</i> , 2015, 10, 373-380.	0.5	54
103	Non-Small Cell Lung Cancer, Version 6.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 515-524.	2.3	323
104	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. <i>Cancer</i> , 2015, 121, 3212-3220.	2.0	160
105	Beyond Second-Line in Non-Small Cell Lung Cancer: Therapy and Supportive Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e414-e418.	1.8	2
106	EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2221-2226.	3.2	72
107	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 1881-1888.	0.8	555
108	Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1666-1673.	0.8	99

#	ARTICLE	IF	CITATIONS
109	Differences in the survival of patients with recurrent versus de novo metastatic KRAS mutant and EGFR mutant lung adenocarcinomas. <i>Cancer</i> , 2015, 121, 2078-2082.	2.0	15
110	Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015, 10, 431-437.	0.5	98
111	Acquired Resistance of EGFR Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor. <i>JAMA Oncology</i> , 2015, 1, 982.	3.4	214
112	Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22160-e22160.	0.8	4
113	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. <i>Cancer Discovery</i> , 2014, 4, 1036-1045.	7.7	348
114	Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?. <i>European Respiratory Journal</i> , 2014, 43, 1240-1242.	3.1	8
115	Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1669-1674.	0.5	106
116	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1118-1127.	2.1	131
117	Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 1189-1197.	13.9	1,367
118	Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1963-1971.	13.9	1,656
119	Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?. <i>Lung Cancer</i> , 2014, 86, 190-194.	0.9	57
120	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1119-1128.	5.1	631
121	Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2014, 20, 5898-5907.	3.2	72
122	Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway. <i>Clinical Lung Cancer</i> , 2014, 15, 475.	1.1	3
123	Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 322-329.	0.4	91
124	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. <i>Cancer</i> , 2013, 119, 356-362.	2.0	143
125	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. <i>Science Translational Medicine</i> , 2013, 5, 216ra177.	5.8	438
126	Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 2240-2247.	3.2	2,097

#	ARTICLE	IF	CITATIONS
127	Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 2584-2591.	3.2	134
128	<i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i> : An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4273-4281.	3.2	521
129	Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 2385-2394.	13.9	3,181
130	Thymomas and Thymic Carcinomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 562-576.	2.3	81
131	Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2013, 8, 346-351.	0.5	313
132	Lungs Don't Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2013, 8, 123-125.	0.5	33
133	The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma. <i>Yonsei Medical Journal</i> , 2013, 54, 865.	0.9	18
134	Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2012, 18, 6169-6177.	3.2	503
135	Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1236-1271.	2.3	312
136	Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1815-1822.	0.5	160
137	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology</i> , The, 2012, 13, 1011-1019.	5.1	1,176
138	Coexistence of <i>PIK3CA</i> and Other Oncogene Mutations in Lung Adenocarcinoma—Rationale for Comprehensive Mutation Profiling. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 485-491.	1.9	191
139	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS</i> , <i>NRAS</i> , or <i>MEK1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2127-33.	3.3	410
140	Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. <i>Cancer</i> , 2012, 118, 5840-5847.	2.0	55
141	Multidisciplinary Management of Thymic Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 466-470.	1.8	1
142	Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2011, 29, 2046-2051.	0.8	616
143	A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1435-1437.	0.5	131
144	Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans. <i>Journal of Thoracic Oncology</i> , 2011, 6, 28-31.	0.5	126

#	ARTICLE	IF	CITATIONS
145	Incorporation of Crizotinib into the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1328-1330.	2.3	18
146	Poly Adenosine Diphosphate-Ribose Polymerase Inhibitors and Heat Shock Protein 90 Inhibitors. Journal of Thoracic Oncology, 2011, 6, S1803-S1804.	0.5	0
147	Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i> -Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design. Clinical Cancer Research, 2011, 17, 6298-6303.	3.2	383
148	Reply to M.C. Garassino et al. Journal of Clinical Oncology, 2011, 29, 3838-3839.	0.8	1
149	Incidence of <i>EGFR</i> Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas. Journal of Clinical Oncology, 2011, 29, 2066-2070.	0.8	247
150	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation. Clinical Cancer Research, 2011, 17, 1616-1622.	3.2	556
151	Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib. Clinical Cancer Research, 2011, 17, 2521-2527.	3.2	116
152	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	0.5	4,127
153	Non-Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 740-801.	2.3	606
154	Induction Therapy For Locally Advanced Thymoma. Journal of Thoracic Oncology, 2010, 5, S323-S326.	0.5	39
155	Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer, 2010, 116, 670-675.	2.0	111
156	Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 357-360.	0.8	735
157	Lung cancer in 'Never-smokers': molecular factors trump risk factors. Oncology, 2010, 24, 38, 40.	0.4	2
158	KRAS Mutations in Non-Small Cell Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 201-205.	3.5	474
159	Impact of Epidermal Growth Factor Receptor and <i>KRAS</i> Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials. Clinical Cancer Research, 2009, 15, 5267-5273.	3.2	382
160	Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 264-270.	0.8	55
161	Multimodality Therapy for Locally Advanced Thymomas: State of the Art or Investigational Therapy?. Annals of Thoracic Surgery, 2008, 85, 365-367.	0.7	19
162	The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer, 2008, 60, S19-S22.	0.9	18

#	ARTICLE	IF	CITATIONS
163	KRAS mutational testing in the selection of patients for EGFR-targeted therapies. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 288-294.	1.0	16
164	Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 7519-7525.	3.2	267
165	Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 5731-5734.	3.2	505
166	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, S146-S149.	0.5	66
167	Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. <i>Clinical Cancer Research</i> , 2008, 14, 7060-7067.	3.2	156
168	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20932-20937.	3.3	1,557
169	Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus. <i>Clinical Cancer Research</i> , 2007, 13, 5150-5155.	3.2	279
170	A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. <i>Lung Cancer</i> , 2007, 55, 181-185.	0.9	56
171	Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 1700-1704.	0.8	202
172	Bronchioloalveolar Carcinoma of the Lung. , 2006, , 313-320.		0
173	Update on Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7232-7241.	3.2	357
174	Clinical Course of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2006, 12, 839-844.	3.2	688
175	Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2006, 12, 6494-6501.	3.2	783
176	KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. <i>PLoS Medicine</i> , 2005, 2, e17.	3.9	1,331
177	Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. <i>PLoS Medicine</i> , 2005, 2, e73.	3.9	3,022
178	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: Is timing important?. <i>Cancer Biology and Therapy</i> , 2005, 4, 1096-1097.	1.5	6